OXER1 as a Radioligand Therapy Target
OXER1, oxoeicosanoid receptor 1, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, OXER1 staining is highest in melanoma (100% of samples positive), pancreatic cancer (100% of samples positive) and neuroendocrine tumors (100% of samples positive). Evidence on whether OXER1 internalizes is mixed. Clinical status: Discovery-stage (no clinical drug program).
Is OXER1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in melanoma, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
OXER1 expression in cancer
Protein expression of OXER1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Melanoma | 0.87 | High | 100% |
| Pancreatic Cancer | 0.85 | High | 100% |
| Neuroendocrine Tumors | 0.83 | High | 100% |
| Prostate Cancer | 0.83 | High | 100% |
| Liver Cancer | 0.83 | High | 100% |
| Ovarian Cancer | 0.80 | High | 100% |
| Head and Neck Cancer | 0.78 | High | 100% |
| Thyroid Cancer | 0.78 | High | 100% |
| Gastric Cancer | 0.76 | High | 100% |
| Testicular Cancer | 0.76 | High | 100% |
| Bladder Cancer | 0.75 | High | 100% |
| Endometrial Cancer | 0.75 | High | 100% |
| Lung Cancer | 0.73 | High | 100% |
| Skin Cancer | 0.67 | High | 100% |
| Colorectal Cancer | 0.67 | High | 100% |
| Breast Cancer | 0.67 | High | 100% |
| Glioma | 0.67 | High | 100% |
| Cervical Cancer | 0.64 | High | 100% |
| Kidney Cancer | 0.64 | High | 91% |
| Lymphoma | 0.28 | Medium | 58% |
Is OXER1 internalized?
Uncertain. Insufficient literature found.
OXER1 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for OXER1 yet. Search ClinicalTrials.gov for OXER1 trials.
OXER1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See OXER1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
OXER1 gene essentiality (DepMap)
CRISPR knockout effect across 1247 cancer cell lines: 0.15 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related melanoma radioligand targets
HER3 (ERBB3) · c-MET (MET) · STEAP2 · SSTR2 · B7-H3 (CD276) · ITGAV · TMEFF2 · FAP
See all radioligand therapy targets in melanoma.
See how OXER1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.